Raptor Pharmaceutical Corp. (NASDAQ:RPTP)’s share price traded down 1.5% during trading on Tuesday . The stock traded as low as $7.22 and last traded at $7.25, with a volume of 434,230 shares trading hands. The stock had previously closed at $7.36.

Several equities research analysts have recently weighed in on RPTP shares. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Raptor Pharmaceutical Corp. in a research report on Friday, May 6th. Cowen and Company reiterated a “buy” rating and set a $8.00 price target on shares of Raptor Pharmaceutical Corp. in a research report on Friday, August 19th. Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a research report on Thursday, August 11th. Citigroup Inc. downgraded shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their price target for the company from $6.00 to $8.00 in a research report on Monday, August 8th. Finally, FBR & Co reiterated a “hold” rating and set a $10.00 price target on shares of Raptor Pharmaceutical Corp. in a research report on Tuesday. Five research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $7.79.

The company has a 50-day moving average price of $6.33 and a 200 day moving average price of $5.16. The stock’s market cap is $594.58 million.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.02. The firm had revenue of $32.05 million for the quarter, compared to the consensus estimate of $28.52 million. The firm’s revenue was up 37.4% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.17) EPS. Equities research analysts expect that Raptor Pharmaceutical Corp. will post ($0.91) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Raptor Pharmaceutical Corp. stock. Schwab Charles Investment Management Inc. increased its stake in shares of Raptor Pharmaceutical Corp. (NASDAQ:RPTP) by 3.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 292,620 shares of the company’s stock after buying an additional 9,354 shares during the period. Schwab Charles Investment Management Inc. owned about 0.34% of Raptor Pharmaceutical Corp. worth $1,522,000 as of its most recent SEC filing.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.